-
2021
Technology evaluation for applicability of the technology-based listing scheme
Signed a license agreement with Pierre Fabre for YBL-003press release
Selected as an Excellent Corporate R&D Institute by the Ministry of Science and ICT
-
2020
Signed a license agreement with Pyxis Oncology for YBL-001 jointly developed with LegoChem Biosciencespress release
Signed a license agreement with 3D Medicines (3D MED) for the China rights of YBL-013press release
Signed a joint R&D agreement with NeoImmuneTech for YBL-018press release
Signed a license agreement on antibody sequence with ViroCure for YBL-006, etc.press release
Signed a license agreement on antibody sequence with GI Innovation for YBL-006, etc.press release
Initiated Phase 1 clinical trials for YBL-006 in Korea, Australia and Thailand
Registered a patent for ALiCE, a bispecific T cell engager platform, in the United States
Received the IR52 Jang Young-shil Award for technological innovation (Minister of Science and ICT)
Series D Funding: Raised 20 billion KRW
-
2018
Series C Funding: Raised 37.4 billion KRW
-
2016
Signed a joint R&D agreement with LegoChem Biosciences for YBL-001
Signed a joint R&D agreement with HK inno.N for the discovery of 3 bispecific antibodies
Series A/B Funding: Raised 15 billion KRW
-
2015
Seed Funding: Obtained 1 billion KRW
-
2012
Conducted joint research & development with Sanofi Aventis on a targeted antibody therapeutic for liver cancer (until 2014)
-
2009
Obtained Venture Business and Corporate R&D Institute certifications
-
2007
Establishment of Y-Biologics, Inc.